BIONTECH SE ADS news, videos and press releases
For more news please use our advanced search feature.
BIONTECH SE ADS - More news...
BIONTECH SE ADS - More news...
- BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
- BioNTech to Acquire Biotheus to Boost Oncology Strategy
- BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
- BioNTech to Host Innovation Series R&D Day on November 14, 2024
- BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
- BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
- BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
- BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
- BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
- BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
- Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
- BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
- BioNTech Announces Planned Retirement of Sean Marett
- BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
- BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
- BioNTech to Inaugurate First African Site on December 18, 2023
- BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
- BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
- Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
- Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
- BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
- BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
- BioNTech Completes Acquisition of InstaDeep
